The US Food and Drug Administration (FDA) approved Oral Immunotherapy (OIT) for peanut allergies and, in 2024, the anti-IgE monoclonal antibody omalizumab, reflecting progress in allergy treatments [8,9]. This evidence concerns the gene IGHE and allergic disease.